Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

No swallow or voice evaluation or treatment were offered to 83.1% of all individuals with myasthenia gravis, 53% of patients with myasthenia gravis and any speech/swallow dysfunction, 43.8% who ...

Decreased AChR-Ab titers correlated with improved myasthenia gravis symptoms, especially in ADL scores, within the first 3 months of treatment. The study found no baseline correlation between AChR ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor ...

THE occurrence of thyrotoxicosis in patients with myasthenia gravis is not rare, over 90 such cases having been reported since the turn of the century. 1,2 Various estimates place the incidence of ...

The company, currently valued at $692 million, is preparing for several significant clinical trial readouts over the next 18 months, including a Phase 2 proof of concept in Myasthenia Gravis (MG), a ...

Upcoming data readouts for betoklamab in myasthenia gravis and CIDP are crucial for ... And so, and then just taking the next step, how do you see broader potential for brepacitinib speak to ...

Upcoming data readouts for betoklamab in myasthenia gravis and CIDP are crucial for Roivant’s strategic ... And so, and then just taking the next step, how do you see broader potential for ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

“FDA approval of TEVIMBRA for the first-line treatment of advanced esophageal squamous cell carcinoma marks a significant step forward ... myasthenic syndrome/myasthenia gravis (including ...